此外，该公司计划继续投资于CAR-T及TCR-T细胞产品管线。今年2月，公司已就aT19注射液取得国家药监局的临床批准。兴业证券此前指出，细胞免疫疗法近年快速成长，展现出极大的潜力。公司深耕细胞免疫治疗领域多年，拥有高度整合的T细胞免疫治疗药物研发平台和生产基地，其管线在多个细分领域均有布局，部分产品的研发进度亦国内领先，有望享受行业成长的红利。Yongtai Biotechnology-B (06978) rose by as much as 28%, and as of press time, it rose by 22.14%, with a transaction volume of HKD 5.4982 million.
According to the Wisdom Wealth App, Yongtai Biotechnology-B (06978) rose by as much as 28%, and as of press time, it rose by 22.14%, with a transaction volume of HKD 5.4982 million.
According to Yongtai Biotechnology's 2023 financial report, the company achieved other income of approximately RMB 10.5 million during the period, a year-on-year increase of approximately 15.4%. It is reported that the company plans to conduct clinical research on the expansion of indications of EAL. Multiple clinical studies have shown that EAL is effective in treating various tumors outside of liver cancer. After the indication approval of EAL for the treatment of liver cancer is listed, the company plans to expand its clinical indications to diseases such as lung cancer, gastric cancer, glioma, and colorectal cancer.
In addition, the company plans to continue investing in the CAR-T and TCR-T cell product pipelines. In February of this year, the company has obtained clinical approval from the National Medical Products Administration for aT19 injection. Industrial Securities previously pointed out that cell immunotherapy has grown rapidly in recent years and has shown great potential. The company has been deeply involved in the field of cell immunotherapy for many years, has a highly integrated T-cell immunotherapy drug R&D platform and production base, has layouts in multiple sub-sectors, and the R&D progress of some products is also leading domestically, and is expected to enjoy industry growth dividends.
Furthermore, the company plans to continue to invest in the CAR-T and TCR-T cell product pipelines. In February of this year, the company has obtained clinical approval from the National Medical Products Administration for aT19 injection. Industrial Securities previously pointed out that cell immunotherapy has grown rapidly in recent years and has shown great potential. The company has been deeply involved in the field of cell immunotherapy for many years, has a highly integrated T-cell immunotherapy drug R&D platform and production base, has layouts in multiple sub-sectors, and the R&D progress of some products is also leading domestically, and is expected to enjoy industry growth dividends.